ACTG A5142 LOPINAVIR/RITONAVIR PLUS EFAVIRENZ FOR HIV -1 INFECTION

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Compare the time to virologic failure pairwise between the three HIV-1 treatments groups, (1) Lopinavir/Ritonavir plus Efavirenz, (2) Lopinavir/Ritonavir plus Stavudine Extended Release (or Zidovudine) plus Lamivudine or (3) Efavirenz plus Stavudine Extended Release (or Zidovudine) plus Lamivudine. Compare time to regimen completion pairwise between the 3 treatment groups. Regimen completion will be defined as either virologic failure or toxicity-related discontinuation of any component of the initial randomized treatment regimen. Compare treatment groups occurrence of peripheral lipoatrophy as measured by limb DEXA. Compare groups with metabolic abnormalities.